New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
10:27 EDTCANFCan-Fite CF102 approved for compassionate use in Israel
Can-Fite BioPharma announced that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. FDA for CF102 in the treatment of advanced hepatocellular carcinoma.
News For CANF From The Last 14 Days
Check below for free stories on CANF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 5, 2014
11:52 EDTCANFCan-Fite receives Japanese patent for liver function treatment after surgery
Can-Fite BioPharma announced earlier the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent Office. The patent covers Can-Fite's clinical stage drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery or other injury via inhibition of pro-apoptotic proteins, resulting in liver repair.
September 2, 2014
07:07 EDTCANFCan-Fite BioPharma reports H1 EPS (NIS71c) vs. last year (NIS1.11)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use